A variety of pharmacologic inhibitors of glycolysis have shown promise in animal models of autoimmune disease, including 2‐deoxyglucose, inhibitors of the glucose transporter GLUT1, and dichloroacetate, which is an inhibitor of the enzyme PDHK1. This evidence concerns the gene PDK1 and autoimmune disease.